Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials
Open accessThe DOI matches its Crossref record; 141 of the 145 references it cites were found in a registry or an index.
Abstract
Obesity is a chronic disease with high prevalence and associated comorbidities, making it a growing global concern. These comorbidities include type 2 diabetes, hypertension, ventilatory dysfunction, arthrosis, venous and lymphatic circulation diseases, depression, and others, which have a negative impact on health and increase morbidity and mortality. GLP-1 agonists, used to treat type 2 diabetes, have been shown to be effective in promoting weight loss in preclinical and clinical studies. This review summarizes numerous studies conducted on the main drugs in the GLP-1 agonists class, outlining the maximum achievable weight loss. Our aim is to emphasize the active role and main outcomes of GLP-1 agonists in promoting weight loss, as well as in improving hyperglycemia, insulin sensitivity, blood pressure, cardio–metabolic, and renal protection. We highlight the pleiotropic effects of these medications, along with their indications, contraindications, and precautions for both diabetic and non-diabetic patients, based on long-term follow-up studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures










Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“GLP‐1 receptor agonists, including liraglutide, semaglutide, and tirzepatide (dual GIP/GLP agonists), have revolutionised the field of obesity pharmacotherapy by facilitating substantial weight loss, achieving an average reduction of 9% with liraglutide, up to 15% with semaglutide, and 18% with tirzepatide [11, 12].”
From Efficacy and Safety of Orforglipron in Obese Adults With or Without Diabetes: A Systematic Review and Meta‐Analysis (2025) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This is a critical consideration, as GLP-1RA treatment duration in patients with obesity is highly variable, ranging up to 24 months depending on weight loss goals.18”
From GLP-1RA-induced delays in gastrointestinal motility: Predicted effects on coadministered drug absorption by PBPK analysis (2025) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“GLP-1RAs, including liraglutide and semaglutide, can induce substantial weight loss (often 10–15% or more), improve cardiometabolic risk factors, including histological damage associated with metabolic dysfunction–associated steatohepatitis (MASH) (3), and reduce major adverse cardiovascular events in both diabetic and non-diabetic populations (1, 4–12).”
From GLP-1 agonists and exercise: the future of lifestyle prioritization (2025) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“GLP-1RAs consistently demonstrate significant weight loss (mean reductions of 7–9 kg of body weight over a period of about a year) and improvements in BMI, waist circumference, blood pressure, and lipid profiles in both diabetic and non-diabetic populations (5–7, 10, 23).”
From GLP-1 agonists and exercise: the future of lifestyle prioritization (2025) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Current evidence strongly supports the efficacy of GLP-1 receptor agonists for inducing substantial weight loss, improving metabolic control, and reducing cardiovascular risk – often surpassing the short-term effects of exercise alone (4–10, 23).”
From GLP-1 agonists and exercise: the future of lifestyle prioritization (2025) · cites this paper as [7]
Experimental — accuracy not yet measured
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2003.10.004 · Cited by 9,050
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 2×
“There were no significant differences in hospitalization rates for non-fatal myocardial infarction, non-fatal stroke, and heart failure between the liraglutide and placebo groups [89].”
BackgroundOnce-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896 · cited 21×
“The first approach aimed at prolonging the hal -life of GLP-1 y i h bitin its degradation by DPP-4 through the d vel pment of DPP-4 inhibitors.”
BackgroundInfluentialTirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
European Guidelines for Obesity Management in Adults
Yumuk, V., Tsigos, C., Fried, M., Schindler, K., Busetto, L., Micic, D., & Toplak, H. (2015) · Obesity Facts · doi:10.1159/000442721 · Cited by 3,432
Zelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Furtado, R. H. M., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32590-x · Cited by 2,845 · cited 2×
“9 kg) resulted in smaller changes [65].”
BackgroundA Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Benjamin, E. J. (1994) · JAMA · doi:10.1001/jama.1994.03510350050036 · Cited by 2,613 · cited 2×
“sclerosis, heart failure [14], and atrial fibrillation [15], while metabolic complications in-”
BackgroundTirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096
Research works printed but not linked: 3
- Al-Omar M.A. Al-Suwailem A.K. Al-Tamimi A.S. Al-Suhibani M.S. Safety and mechanism of action of orlistat (tetrahydrolipstatin) as the first local antiobesity drug J. Appl. Sci. Res. 2006 2 205 208
- Kanwal S. AlEmadi E.A. Liraglutide for Weight Management, Critical Analysis of Efficacy and Side effects in Non diabetic, individuals with obesity: A Comprehensive Systematic Review Middle East J. Fam. Med. 2021 19 72 83
- Clinical Review Report: Semaglutide (Ozempic): (Novo Nordisk Canada Inc.): Indication: For the Treatment of Adult Patients with Type 2 Diabetes Mellitus to Improve Glycemic Control, in Combination with Metformin (Second-Line Treatment), and in Combination with Metformin and Sulfonylurea (Third-Line Treatment) [Internet] Canadian Agency for Drugs and Technologies in Health Ottawa, ON, Canada 2019 31305971
Cited by
Młynarska, E., Czarnik, W., Dzieża, N., Jędraszak, W., Majchrowicz, G., Prusinowski, F., Stabrawa, M., Rysz, J., & Franczyk, B. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26031094 · Cited by 328
“Furthermore, nasopharyngitis and headaches associated with injections may occasionally occur [107].”
Wong, H. J., Sim, B., Teo, Y. H., Teo, Y. N., Chan, M. Y., Yeo, L. L. L., Eng, P. C., Tan, B. Y. Q., Sattar, N., Dalakoti, M., et al. (2025) · Diabetes Care · doi:10.2337/dc24-1678 · Cited by 208
Silverii, G. A., Monami, M., Gallo, M., Ragni, A., Prattichizzo, F., Renzelli, V., Ceriello, A., & Mannucci, E. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15382 · Cited by 113
“3,4 The safety of GLP-1RAs has been confirmed by large-scale randomized trials, usually with cardiovascular primary endpoints.”
Cardiovascular Effects and Tolerability of GLP-1 Receptor Agonists
Galli, M., Benenati, S., Laudani, C., Simeone, B., Sarto, G., Ortega‐Paz, L., Rocco, E., Bernardi, M., Spadafora, L., D’Amario, D., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.08.027 · Cited by 140
Chiang, C.-H., Jaroenlapnopparat, A., Colak, S. C., Yu, C.-C., Xanthavanij, N., Wang, T.-H., See, X. Y., Lo, S.-W., Ko, A., Chang, Y.-C., et al. (2025) · Gastroenterology · doi:10.1053/j.gastro.2025.06.003 · Cited by 105
Chen, Y., Guan, M., Wang, R. L., & Wang, X. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1298345 · Cited by 93
Popoviciu, M. S., Păduraru, L., Nutas, R. M., Ujoc, A. M., Yahya, G., Metwally, K. A., & Cavalu, S. D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241612676 · Cited by 108
Self-citationBuddhiraju, A., Kagabo, W., Khanuja, H. S., Oni, J. K., Nikkel, L. E., & Hegde, V. V. (2024) · The Journal of Arthroplasty · doi:10.1016/j.arth.2024.05.079 · Cited by 84
Aldhaleei, W. A., Abegaz, T. M., & Bhagavathula, A. S. (2024) · Pharmaceuticals · doi:10.3390/ph17020199 · Cited by 80
“They are also used as an adjunct for weight loss in people without diabetes [7].”
Młynarska, E., Bojdo, K., Bulicz, A., Frankenstein, H., Gąsior, M., Kustosik, N., Rysz, J., & Franczyk, B. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47100787 · Cited by 106
“Despite promising data, the complexity of GLP-1’s effects highlights the need for further research, especially in real-life settings and comorbid conditions such as fatty liver disease [131].”
GLP ‐1 receptor agonists and the risk for cancer: A meta‐analysis of randomized controlled trials
Silverii, G. A., Marinelli, C., Bettarini, C., Del Vescovo, G. G., Monami, M., & Mannucci, E. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.16489 · Cited by 67
Kim, B. I., LaValva, S. M., Parks, M. L., Sculco, P. K., Valle, A. G. D., & Lee, G. (2024) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.24.00468 · Cited by 76
NCCN Guidelines® Insights: Survivorship, Version 2.2025
Sanft, T. B., Day, A. T., Ansbaugh, S. M., Ariza‐Heredia, E., Armenian, S. H., Baker, K. S., Ballinger, T. J., Cathcart-Rake, E. J., Cohen, S. H., Evgeniou, E., et al. (2025) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2025.0028 · Cited by 78
Weight Reduction with GLP-1 Agonists and Paths for Discontinuation While Maintaining Weight Loss
Reiss, A. B., Gulkarov, S., Lau, R., Klek, S. P., Srivastava, A., Renna, H. A., & De Leon, J. (2025) · Biomolecules · doi:10.3390/biom15030408 · Cited by 58
“GLP-1 receptor agonist drug development began in earnest in 2005 with the approval of exenatide, a synthetic form of a natural peptide hormone isolated from the saliva of the venomous lizard Gila monster [144].”
Hamed, K. M., Alosaimi, M. N., Ali, B. A., Alghamdi, A. M., Alkhashi, T., Alkhaldi, S. S., Altowarqi, N. A., Alzahrani, H., Alshehri, A., Alkhaldi, R. K., et al. (2024) · Cureus · doi:10.7759/cureus.68390 · Cited by 96
“Healthcare organizations may have to modify their infrastructure to accommodate GLP-1-RAs users [61,120].”
BackgroundEbrahimi, P., Batlle, J. C., Ayati, A., Maqsood, M. H., Long, C., Tarabanis, C., McGowan, N., Liebers, D. T., Laynor, G., Hosseini, K., et al. (2025) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2025.0091 · Cited by 51
Gasiorek, A., Heydorn, A., Gabery, S., Hjerpsted, J. B., Kirkeby, K., Kruse, T., Petersen, S. B., Toubro, S., Vegge, A., & Key, C. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01176-6 · Cited by 46
A cost comparison of GLP-1 receptor agonists and bariatric surgery: what is the break even point?
Docimo, S., Shah, J., Warren, G., Ganam, S., Sujka, J., & DuCoin, C. (2024) · Surgical Endoscopy · doi:10.1007/s00464-024-11191-1 · Cited by 46
The signaling pathways in obesity‐related complications
Chandrasekaran, P., & Weiskirchen, R. (2024) · Journal of Cell Communication and Signaling · doi:10.1002/ccs3.12039 · Cited by 55
“145 In Liraglutide, structural modifications were made to GLP ‐ 1 to extend its half ‐ life to 13 h. 146 Similarly, in Semaglutide, Lys26 was attached to a hydrophobic C ‐ 18 fatty di ‐ acid moiety to inhibit glomerular filtration.”
BackgroundAnti-Diabetic Therapies and Cancer: From Bench to Bedside
Kounatidis, D. C., Vallianou, N. G., Karampela, Ι., Rebelos, E., Kouveletsou, M., Dalopoulos, V., Koufopoulos, P., Diakoumopoulou, E., Tentolouris, N., & Dalamaga, Μ. (2024) · Biomolecules · doi:10.3390/biom14111479 · Cited by 52
“Nonetheless, given their impact on weight reduction, these therapies may, under certain conditions, offer protective effects against malignancy [14,15].”
Chang, M. G., Ripoll, J. G., Lopez, E., Krishnan, K., & Bittner, E. A. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13216336 · Cited by 43
Ko, A., Chang, Y.-C., Bahar, F., Wang, T. H., Xanthavanij, N., Yu, C.-C., Hsieh, R. J.-L., See, X. Y., Lo, S., Song, J., et al. (2025) · Annals of Internal Medicine · doi:10.7326/annals-25-02237 · Cited by 59
Kuo, C., Chuang, M., Li, C., Tsai, Y., Huang, P., Kuo, H., & Lai, C. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.18502 · Cited by 44
Daneshgaran, G., Shauly, O., & Gould, D. J. (2025) · Aesthetic Surgery Journal Open Forum · doi:10.1093/asjof/ojaf056 · Cited by 47
“41 Attention should be paid to patients taking multiple newer antidiabetic medications, such as GLP-1 receptor agonists taken in combination with SGLT-2 inhibitors, because they are at greater risk of experiencing medication adverse effects potentially requiring hospitalization.”
Ngabea, M. A., & Dimeji, I. Y. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152822 · Cited by 35
Ramírez-Mejía, M. M., Ponciano‐Rodríguez, G., Eslam, M., & Méndez-Sánchez, N. (2025) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188251406456 · Cited by 45
Amin, N. B., Frederich, R. C., Tsamandouras, N., Haggag, A. Z., Schuster, T., Żmuda, W., Palmer, A., Vasas, S., Buckley, G., Smith, T. R., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16005 · Cited by 37
Gentinetta, S., Sottotetti, F., Manuelli, M., & Cena, H. (2024) · Diabetes, Metabolic Syndrome and Obesity · doi:10.2147/dmso.s494919 · Cited by 32
“2,3 There are different types of drugs that have been developed through the years; among these, GLP-1 receptor agonists (GLP-1RAs) are known for their safety and efficacy 4 due to their ability to act at the hypothalamic influencing hunger and fullness, and consequently reducing caloric intake.”
Hooper, L., Liu, S., & Pai, M. P. (2025) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.70007 · Cited by 32
Obesity-Related Chronic Kidney Disease: From Diagnosis to Treatment
Avgoustou, E., Tzivaki, I., Diamantopoulou, G., Zachariadou, T., Avramidou, D., Dalopoulos, V., & Skourtis, A. (2025) · Diagnostics · doi:10.3390/diagnostics15020169 · Cited by 39
“Apart from their use as antidiabetic medications in patients with type 2 diabetes, they have been approved for weight management in individuals who are overweight or obese [109,110].”
Targeting mitochondrial transporters and metabolic reprogramming for disease treatment
Anselme, M., He, H., Lai, C., Luo, W., & Zhong, S. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06976-4 · Cited by 37
Kim, B. I., Khilnani, T. K., LaValva, S. M., Goodman, S. M., Valle, A. G. D., & Lee, G. (2024) · The Journal of Arthroplasty · doi:10.1016/j.arth.2024.12.008 · Cited by 33
The hidden impact of GLP ‐1 receptor agonists on endometrial receptivity and implantation
Sola‐Leyva, A., Pathare, A. D. S., Apostolov, A., Aleksejeva, E., Kask, K., Tammiste, T., Ruiz‐Durán, S., Risal, S., Acharya, G., & Salumets, A. (2024) · Acta Obstetricia Et Gynecologica Scandinavica · doi:10.1111/aogs.15010 · Cited by 35
The prevention and management of chronic kidney disease among patients with metabolic syndrome
Zhu, D., Judge, P. K., Wanner, C., Haynes, R., & Herrington, W. G. (2025) · Kidney International · doi:10.1016/j.kint.2024.12.021 · Cited by 38
How Biologics Have Changed the Drug Discovery Landscape
McGonigle, P. (2024) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-061724-080811 · Cited by 32
Wong, H. J., Toh, K. Z. X., Teo, Y. H., Teo, Y. N., Chan, M. Y., Yeo, L. L. L., Eng, P. C., Tan, B. Y., Zhou, X., Yang, Q., et al. (2024) · Journal of Hypertension · doi:10.1097/hjh.0000000000003903 · Cited by 29
“O besity carries significant morbidity and mortality, 2 diabetes mellitus (T2DM), but are increasingly being used as weight loss medications [2].”
Safwan, M., Bourgleh, M. S., Alotaibi, S. A., Alotaibi, E. A., Al-Ruqi, A., & Raeya, F. E. (2025) · Annals of Saudi Medicine · doi:10.5144/0256-4947.2025.129 · Cited by 78
Alexander, G. C., Xiao, X., Dilek, S., Lewis, S. V., Deng, Q., Kim, M., Bolanle, D., Saldanha, I. J., & Mehta, H. B. (2026) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2025.8222 · Cited by 30
Drug treatment for metabolic dysfunction-associated steatotic liver disease: Progress and direction
Zhou, D., & Fan, J. (2024) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003355 · Cited by 30
Effect of GLP-1 receptor agonists on weight and cardiovascular outcomes: A review
Raza, F. A., Altaf, R., Bashir, T., Asghar, F., Altaf, R., Tousif, S., Goyal, A., Mohammed, A., Mohammad, M. F., Anan, M., et al. (2024) · Medicine · doi:10.1097/md.0000000000040364 · Cited by 37
Pourhassan, H., Murphy, L. A., & Aldoss, I. T. (2024) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-024-00735-w · Cited by 26
“Glucagon-like peptide-1 (GLP-1) analogues and other obesity interventions are gaining significant attention in the obesity epidemic [116, 117] and could perhaps also be an added area of exploration for ways to overcome the adverse effects of GC use that is vital to ALL therapy.”
BackgroundKopp, K. O., Li, Y., Glotfelty, E. J., Tweedie, D., & Greig, N. H. (2024) · Biomolecules · doi:10.3390/biom14070872 · Cited by 27
“Glucagon-like peptide-1 (GLP-1) and, more recently, glucose-dependent insulinotropic polypeptide (GIP) and glucagon (Gcg) receptor (R) agonists have revolutionized T2DM and obesity treatment, restoring insulin sensitivity and often facilitating weight loss in patients [1,2].”
BackgroundHow ‘miracle’ weight‐loss semaglutide promises to change medicine but can we afford the expense?
Weiskirchen, R., & Lonardo, A. (2025) · British Journal of Pharmacology · doi:10.1111/bph.70003 · Cited by 30
“…including a new class of therapy mimicking the gut hormone glucagon-like peptide-1 (GLP-1), the advent of semaglutide promises to curtail the rates of obesity and interlinked chronic diseases, thus reshaping medicine, popular culture, and the world of health economics (Popoviciu et al., 2023).”
Obesity and early-onset colorectal cancer risk: emerging clinical evidence and biological mechanisms
Xu, P., Tao, Z., Yang, H., & Zhang, C. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1366544 · Cited by 39
“Interestingly, glucagon-like peptide-1 (GLP-1) agonists play an effective role in treating type 2 diabetes and preventing obesity (152).”
BackgroundButucă, A., Dobrea, C. M., Arseniu, A. M., Frum, A., Chiş, A. A., Rus, L. L., Ghibu, S., Juncan, A. M., Muntean, A. C., Lazăr, A. E., et al. (2024) · Biomedicines · doi:10.3390/biomedicines12051124 · Cited by 31
“Based on this information, it could be considered that the people interested in these molecules had similar search behavior regarding the safety of the products.”
BackgroundChang, M. G., & Bittner, E. A. (2024) · Canadian Journal of Anesthesia/Journal canadien d anesthésie · doi:10.1007/s12630-024-02810-5 · Cited by 26
Wu, J., Tseng, K., Kao, C., Hung, K.-C., Yu, T., & Lin, Y. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112279 · Cited by 26
Obesity in Hidradenitis Suppurativa: Are GLP-1 Receptor Agonists the New Frontier?
Strong, J., & Driscoll, M. S. (2024) · American Journal of Clinical Dermatology · doi:10.1007/s40257-024-00911-x · Cited by 22
Tan, Y. W., Shang, M., Davis, S., & Gananadha, S. (2025) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-025-03831-4 · Cited by 24
Szukiewicz, D. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26062501 · Cited by 25
Buonanno, S., Gaggiano, C., Terribili, R., Cantarini, L., Frediani, B., & Gentileschi, S. (2025) · Inflammation Research · doi:10.1007/s00011-025-02140-2 · Cited by 23
Choudhury, A., Boxtel, M. V., & Hanley, J. (2024) · Seminars in Arthroplasty JSES · doi:10.1053/j.sart.2024.10.001 · Cited by 21
Catalfamo, L. M., Ponte, F. S. D., & Rinaldis, D. D. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14155269 · Cited by 25
“Furthermore, due to their weight-reducing properties, these agents have also gained regulatory approval for the management of obesity in individuals with obesity-related comorbidities [10].”
Understanding peptide hormones: from precursor proteins to bioactive molecules
Voilquin, L., Wiggenhorn, A. L., & Svensson, K. J. (2025) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2025.03.014 · Cited by 20
O’Leary, S., Price, A., Camarillo‐Rodriguez, L., Costa, M. L., Karas, P. J., Young, C. C., Srinivasan, V. M., & Kan, P. T. M. (2025) · Journal of neurosurgery · doi:10.3171/2025.1.jns242357 · Cited by 25
A combinatorial siRNA and mRNA approach for obesity treatment using targeting lipid nanoparticles
Stewart, W., Hu, B., Li, F., Huang, J., Liu, Z., Zhang, C., Tang, M., Zhang, X., & Xu, X. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113857 · Cited by 19
Wulff, B. S., Chambers, A. P., Contreras, C. K. O., Kirkeby, K., Rinnov, A. R., Sustarsic, R. K., Østergaard, S., Laabs, J. E., & O'Neil, P. M. (2025) · Obesity · doi:10.1002/oby.24329 · Cited by 19
“Glucagon-like peptide-1 (GLP-1) receptor agonists, such as once-daily liraglutide and once-weekly semaglutide, play significant roles in the treatment of obesity and type 2 diabetes as an adjunct to diet and exercise [1, 2].”
Odah, T., Vattikonda, A., Stark, M. E., Brahmbhatt, B. S., Lukens, F., Badurdeen, D., Hashash, J. G., & Farraye, F. A. (2024) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2024.07.014 · Cited by 18
GLP-1 agonists and exercise: the future of lifestyle prioritization
Codella, R., Senesi, P., & Luzi, L. (2025) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2025.1720794 · Cited by 16
“…and metabolic health GLP-1RAs consistently demonstrate signi fi cant weight loss (mean reductions of 7 – 9 kg of body weight over a period of about a year) and improvements in BMI, waist circumference, blood pressure, and lipid pro fi les in both diabetic and non-diabetic populations (5 – 7, 10, 23).”
The Inappropriate Use of GLP-1 Analogs: Reflections from Pharmacoepidemiology
Echeverry-Guerrero, S., González-Vélez, S., Arévalo-Lara, A.-S., Calvache-Orozco, J.-C., Villarroel-Hagemann, S. K., Rojas-Rodríguez, L. C., Pérez-Acosta, A. M., & Calderón‐Ospina, C. (2024) · Pharmacoepidemiology · doi:10.3390/pharma3040025 · Cited by 21
“Furthermore, randomized controlled trials have consistently shown that GLP-1 RAs, particularly semaglutide, can achieve weight loss comparable to bariatric surgery, with reductions of up to 10–15% in body weight [8–10].”
Therapeutic Potential of GLP-1 Receptor Agonists in Metabolic Associated Steatotic Liver Disease
Nowak, K., Łupina, K., Romac, A., Kalisz, A., Ilkiewicz, Ł., & Janczura, J. (2025) · Annals of Pharmacotherapy · doi:10.1177/10600280251322002 · Cited by 21
“37,38 GLP-1 RAs have pleiotropic effects, leading to a reduction in liver inflammation and steatosis and a reduction in fibrosis progression by decreasing appetite, slowing gastric emptying, decreasing body weight, increasing insulin sensitivity of muscle cells and increasing insulin and improving…”
Metabolic Modulators in Depression: Emerging Molecular Mechanisms and Therapeutic Opportunities
Dyndał, K., Pańczyszyn-Trzewik, P., & Sowa-Kućma, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178755 · Cited by 19
“Their central actions provide additional benefits in obesity management, including reductions in body weight, appetite, food cravings, and total energy intake, along with enhanced satiety and the improved regulation of eating behavior [39].”
Survival and Recurrence With GLP-1 Receptor Agonists in Breast Cancer
Tatum, K. L., Dahman, B. A., Stevenson, A., Williford, S. E., Cassel, J. B., Zhao, H., Shen, J., McGuire, K. P., Diala, O. R., Oladimeji, R., et al. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.12133 · Cited by 20
GLP-1R agonists: recent advances, current gaps, and future challenges
Saran, A., Raisinghani, R., Paliwal, S., & Sharma, S. K. (2025) · Molecular Diversity · doi:10.1007/s11030-025-11195-6 · Cited by 19
Hachuła, M., Basiak, M., Kosowski, M., & Okopień, B. (2024) · Life · doi:10.3390/life14060690 · Cited by 18
“Additional studies, especially randomized clinical trials with long-term observation, are needed to un-questionably assess the effect of this group of drugs on the development of atherosclerotic cardiovascular disease.”
BackgroundAhmad, N., Alruwayyes, A., AlArjani, A., Tawhari, A. M., Aldosri, A., Alahmari, A., & Balaha, M. F. H. (2026) · Medicine · doi:10.1097/md.0000000000047994 · Cited by 18
“[16] This meta-analysis of 16 RCTs involving 7024 participants found that GLP-1 agonists effectively lowered body weight compared with placebo.”
Use of glucagon-like-peptide 1 receptor agonist in the treatment of childhood obesity
Kavarian, P., MOSHER, T. E., & Haija, M. A. E. (2024) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000001379 · Cited by 19
The importance of patient engagement in the multimodal treatment of MASLD
Boeckmans, J., Hagström, H., Cryer, D. R. H., & Schattenberg, J. M. (2025) · Communications Medicine · doi:10.1038/s43856-025-00871-1 · Cited by 19
Weng, J., Alizadeh, M. A., & Friedman, S. (2025) · Digestive Diseases and Sciences · doi:10.1007/s10620-025-09344-w · Cited by 16
Lorenc, Z. P., Somenek, M. T., Nguyen, T. Q., Garimella, S., Hicks, J. L., Le, J. H. T. D., & Meckfessel, M. (2025) · Aesthetic Surgery Journal · doi:10.1093/asj/sjaf240 · Cited by 15
Zhao, Y., Jiang, L., Li, N., Cao, J., & Pi, J. (2025) · Reproductive Sciences · doi:10.1007/s43032-025-01788-9 · Cited by 14
“While metformin primarily targets insulin resistance and hepatic glucose production, GLP1RAs provide additional metabolic benefits, including enhanced weight loss and appetite suppression [6 , 12 ].”
Bridging ADHD and Metabolic Disorders: Insights into Shared Mechanisms and Clinical Implications
Marcelli, I., Capece, U., & Caturano, A. (2025) · Diabetology · doi:10.3390/diabetology6050040 · Cited by 21
“For instance, GLP-1 receptor agonists have shown promise in combating obesity while potentially enhancing cognitive function [162,163].”
GLP-1 and Its Role in Glycogen Production: A Narrative Review
Lotosky, J., Jean, X., Altankhuyag, A., Khan, S. R., Bernotas, A., Sharafshah, A., Blum, K., Posner, A. R., & Thanos, P. K. (2025) · Biomedicines · doi:10.3390/biomedicines13071610 · Cited by 17
“…surrounding the mechanisms of GLP-1 activity on glycogen metabolism, energy expenditure, and the relevant systems that interplay in inducing these states that can potentially explain the decreases in body weight seen in patients taking GLP-1 agonists, with effects summarized in Figure 1 [6].”
Boianelli, A., Nordell, P., Earl, J., Naylor, J., Hornigold, D. C., Jansson‐Löfmark, R., & Sundqvist, M. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16101310 · Cited by 15
“GLP-1RAs have been used to treat T2DM for almost two decades and have more recently been approved for the treatment of obesity since 2015 (reviewed in Popoviciu et al. 2023 [3,4]).”
MethodMoka, M. K., Sriram, D. K., & George, M. (2024) · Clinical Therapeutics · doi:10.1016/j.clinthera.2024.11.015 · Cited by 19
Ghali, A. N., Lawand, J. J., Mitchell, P., Momtaz, D., Ghilzai, U. M., Phan, E. N., Alawa, J., & Deveza, L. R. (2025) · Clinical Spine Surgery A Spine Publication · doi:10.1097/bsd.0000000000001800 · Cited by 17
Obesity Epidemic and Its Impact on Female Fertility: Current Understanding and Future Directions
Malhotra, R., de Paredes, J. G., Smith, A. C., Chemerinski, A., Doshi, D., & Morelli, S. S. (2025) · Cureus · doi:10.7759/cureus.87283 · Cited by 26
“They work through numerous mechanisms to reduce weight [84,85].”
Nicolau, J., Nadal, A., Sanchís, P., Pujol, A., Tamayo, M. I., Sfondrini, G., Grimalt, M., García, P., Nadal, C., & Masmiquel, L. (2025) · Clinical and Experimental Dermatology · doi:10.1093/ced/llaf473 · Cited by 16
Mahapatro, A., Bozorgi, A., Obulareddy, S. U. J., Jain, S. M., Korsapati, R. R., Kumar, A., Patel, K., Moghadam, S. S., Arya, A., Alotaibi, A. J., et al. (2024) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000002592 · Cited by 15
Le Roux, C. W., Koroleva, A., Larsen, S., & Foot, E. (2025) · Clinical Obesity · doi:10.1111/cob.12704 · Cited by 11
“7,9 Finally, bariatric surgery is a generally effective intervention with good safety outcomes 10,11 ; however, due to system capacity and resource constraints, its use tends to be limited to less than 3% of the eligible population.”
ACTION-FRANCE: Insights into Perceptions, Attitudes, and Barriers to Obesity Management in France
Salle, L., Foulatier, O., Coupaye, M., Fréring, V., Constantin, A., Joly, A.-S., Braithwaite, B., Gharbi, F., & Jubin, L. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13123519 · Cited by 11
GLP-1 Agonists in Patients With Hidradenitis Suppurativa: A Case Series
Rames, M. M., Alavi, A., & Aghazadeh, N. (2025) · Journal of Cutaneous Medicine and Surgery · doi:10.1177/12034754251320045 · Cited by 11
Weight Recidivism After Bariatric Surgery: A Narrative Review
Cao, Q., Kazi, H., Merchant, A. M., & Jawed, A. E. (2025) · The American Surgeon · doi:10.1177/00031348251337161 · Cited by 14
“61 Tirzepatide further builds on this mechanism by combining GLP-1 receptor agonism with GIP receptor activation, a dual-action approach that enhances insulin sensitivity and further reduces appetite.”
Semaglutide - properties, action and chromatographic analysis
Wasilewska, B., & Petruczynik, A. (2025) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-025-01711-8 · Cited by 13
“1 The structure of GLP-1-parent [ 14 ] rash, angioedema and photosensitivity).”
Alfehaid, L., Yami, M. S. A., Almohareb, S. N., Alshaya, O. A., & Almutairi, A. R. (2025) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2025.2465870 · Cited by 13
“The remaining GLP-1 RAs have been used off-label due to the unavailability or high cost of the three approved medications [15,16] Prescriptions for GLP-1 RAs medications have seen a significant rise in recent years.”
Pereira, M. F., Soares, I. D. C., Cabral, M. M., de Freitas, P. A., Sousa, G. M. D. A., Magalhães, S. C., Carioca, A. A. F., de Oliveira, M. R. C., Magalhães, F. E. A., de Oliveira, A. C., et al. (2025) · Nutrients · doi:10.3390/nu17050888 · Cited by 14
“…cacy in reducing body weight in both patients with diabetes These mechanisms, which involve slowing gastric emptying and modulating appetite, may therefore be related to the FOSs present in yacon syrup, reinforcing its impact on weight loss and metabolic control [37]. and non-diabetic individuals.”
Zakir, S. K., Jawed, B., Esposito, J. E., Kanwal, R., Pulcini, R., Martinotti, R., Ceci, E., Botteghi, M., Gaudio, F., Toniato, E., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136043 · Cited by 11
“Future research should consider baseline variations when understanding mechanisms and variables regulating hormone reactivity [55,76,83–85].”
Borges, R. D. S., de Abreu, E. S., Berton, G. G., de Paula, L. H., Conegundes, A. F., Martins, J. M. B., Martins, M. A. B., Dahbour, A., Fernandes, M. V., & Abdelmalek, M. F. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101708 · Cited by 14
“17,18 GLP-1 RAs have achieved up to 20% weight loss and 2.1% HbA1c reduction, 19,20 sparking interest in their potential therapeutic role in MASLD, a disease closely linked to obesity and T2DM.”
InfluentialPandey, R. K., Jan, M., Mohammad, A., Jawaid, K. A., Naveed, M., Abid, M. A., Amir, A. B., Ahmed, S., Safiullah, M., Bhatti, M. I., et al. (2025) · Endocrinology, Diabetes & Metabolism · doi:10.1002/edm2.70134 · Cited by 9
“…including liraglutide, semaglutide, and tirzepatide (dual GIP/ GLP agonists), have revolutionised the field of obesity pharmacotherapy by facilitating substantial weight loss, achieving an average reduction of 9% with liraglutide, up to 15% with semaglutide, and 18% with tirzepatide [11, 12].”
Gul, U., Aung, T., Martin, M., Farrukh, D. N., Shah, P., Lovely, Z. S., León, E. M., Alansaari, M., Maini, S., Fariduddin, M. M., et al. (2024) · Cureus · doi:10.7759/cureus.76519 · Cited by 16
Cazac, G.-D., Lăcătușu, C.-M., Grigorescu, E.-D., Foșălău, A.-B., Onofriescu, A., & Mihai, B. M. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14041042 · Cited by 10
“Soon after, GLP-1RAs were approved for the treatment of obesity without diabetes, as they can facilitate a significant degree of weight loss [42–45].”
Peptidic Tryptophan Halogenation by a Promiscuous Flavin‐Dependent Enzyme
Rice, A. J., Gadgil, M. G., Bisignano, P., Stein, R. A., Mchaourab, H. S., & Mitchell, D. A. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202509729 · Cited by 9
“After in vitro transcription/translation and reaction with ChlH, the samples were subjected to MS analysis to determine chlorination stoichiometry and location (Figures 5, S41-49, and Supplementary Data Set 1).”
Ma, T., Song, F., Pan, Y., He, Y., Cao, X., Zhang, Y., Song, G., & Ren, L. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1659233 · Cited by 10
“It can effectively induce weight loss, optimize glucose homeostasis, enhance insulin sensitivity, and provide cardiovascular and renal benefits (7).”
Medical weight loss in older persons with obesity
Gavras, A., & Batsis, J. A. (2024) · Clinical Obesity · doi:10.1111/cob.12684 · Cited by 10
Cooper, I. D., Kyriakidou, Y., Petagine, L., Edwards, K., Soto-Mota, A., Brookler, K. H., & Elliott, B. (2024) · Biomedicines · doi:10.3390/biomedicines12071553 · Cited by 9
“Lifestyle practices that stimulate chronic excess insulin demand and secretion result in lower GLP-1 levels and, therefore, less GLP-1 receptor (GLP-1R) activation, which is associated with increased insulin resistance, obesity, and T2DM [74].”
BackgroundA Qualitative Analysis of Patient Experiences Using Semaglutide 2.4 mg for Weight Loss
Plenn, E., Amin, D., Henry, J., Leavitt, G., Walker, J., & Soleymani, T. (2025) · Obesity Science & Practice · doi:10.1002/osp4.70085 · Cited by 8
Nonogaki, K., & Kaji, T. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25147784 · Cited by 9
“In addition, liraglutide delays gastric emptying and induces weight loss through reductions in appetite and energy intake [1–3].”
BackgroundAlluri, A. A., Guntupalli, Y., Suvarna, S. S., Prystupa, Y., Khetan, S. P., Vejandla, B., & Swathi, N. L. (2025) · Journal of Basic and Clinical Physiology and Pharmacology · doi:10.1515/jbcpp-2025-0031 · Cited by 11
Spexin is a biomarker of the process that regulates leptin sensitivity
Ahmed, M. B., Habib, A. M., Badran, S. M., Alsherawi, A., Syed, A., Khoogaly, H., Hammouda, A., Abou‐Samra, A., & Doi, S. A. R. (2025) · Peptides · doi:10.1016/j.peptides.2025.171416 · Cited by 8
Ipaye, T., Goldney, J., Wilkinson, T. J., Zaccardi, F., Yates, T. E., Davies, M. J., Brown, K., & Papamargaritis, D. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70090 · Cited by 9
“26,27 In the present study, we adopted an active-comparator, drug-initiator, cohort design, using dipeptidyl peptidase-4 inhibitors (DPP-4i) as a comparator, in the large electronic health records network, TriNetX, to investigate the association of semaglutide, tirze-patide and BS with the rate of…”
Metadata
- Authors
- Popoviciu, M.-S., Păduraru, L., Yahya, G., Metwally, K., & Cavalu, S.
- Affiliations
- University of Oradea (RO)
- University of Kaiserslautern (DE)
- Zagazig University (EG)
- Corresponding author
- Cavalu, Simona
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2023-06-21
- Volume
- 24
- Issue
- 13
- Pages
- 10449
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC10341852
- OpenAlex
- W4381618228
- Semantic Scholar
- f13196d495574d64dbe2e547bd587bb48816b847
- Cited by
- 280
- References
- 145
- Citations by year
- 2026: 70 · 2025: 131 · 2024: 67 · 2023: 12
- FWCI
- 10.17
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- University of Oradea
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- GLP-1 receptor agonists, obesity, weight loss, type 2 diabetes, hyperglycemia, insulin sensitivity, blood pressure, cardioprotection, renal protection, obesity-related comorbidities, long-term safety, non-diabetic patients
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Liraglutide, Exenatide, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Obesity, Peptides, Weight Loss, Randomized Controlled Trials as Topic, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.